Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal
about
The pre-synaptic motor nerve terminal as a site for antibody-mediated neurotoxicity in autoimmune neuropathies and synaptopathiesStreptococcal mimicry and antibody-mediated cell signaling in the pathogenesis of Sydenham's chorea.Anti-GQ1b antibody syndrome: anti-ganglioside complex reactivity determines clinical spectrum.Pathogenesis of Guillain-Barre syndrome.Antiglycolipid antibodies in Guillain-Barré syndrome and related diseases: review of clinical features and antibody specificities.The immunobiology of Guillain-Barré syndromes.Neurofascin as a novel target for autoantibody-mediated axonal injuryEpidermal transient receptor potential vanilloid 1 in idiopathic small nerve fibre disease, diabetic neuropathy and healthy human subjects.Basic and clinical aspects of autoimmune disorders in peripheral nerves.Guillain-Barré syndrome and its treatment.Anti-GM2 ganglioside antibodies are a biomarker for acute canine polyradiculoneuritis.Gangliosides as targets for autoimmune injury to the nervous system.Antiganglioside antibodies and their pathophysiological effects on Guillain-Barré syndrome and related disorders--a review.Pathophysiological actions of neuropathy-related anti-ganglioside antibodies at the neuromuscular junction.An update in guillain-barré syndromeFamilial Miller Fisher syndrome.Dissecting the Role of Anti-ganglioside Antibodies in Guillain-Barré Syndrome: an Animal Model Approach.C1q-targeted inhibition of the classical complement pathway prevents injury in a novel mouse model of acute motor axonal neuropathy.Guillain-Barré syndrome: a century of progress.Animal models for studying motor axon terminal paralysis and recovery.Autoantibody pathogenicity in a multifocal motor neuropathy induced pluripotent stem cell-derived model.Co-cultures with stem cell-derived human sensory neurons reveal regulators of peripheral myelination.The effects of age and ganglioside composition on the rate of motor nerve terminal regeneration following antibody-mediated injury in mice.Detection and prevalence of alpha-latrotoxin-like effects of serum from patients with Guillain-Barré syndrome.Synthesis of ganglioside epitopes for oligosaccharide specific immunoadsorption therapy of Guillian-Barré syndrome.Unusual neurophysiological and immunological findings in myasthenia gravis: a case report.Bilateral oculomotor synkinesis following Miller Fisher syndrome.The relation of clinical symptoms and anti-ganglioside antibodies to MEPPs frequency increase in 8 cases of variant type Guillain-Barré syndrome.Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model.
P2860
Q27004097-FDF904AA-E2A3-4573-BB64-B9CF5F82B247Q34491027-6D7BD0CA-75EE-449C-9902-DBEED429E8F7Q35692197-2BCBF2C3-DE57-4F8A-A199-A70346BFCFDBQ35917297-90D3D73C-BBBE-4902-9A6A-ECE5167E8603Q36019417-E33931AA-DD69-46CB-AC08-B5FCA318B326Q36164122-03478D88-3C01-468E-9765-FCAE280375C3Q36228999-F8093C3F-9FC2-43DC-BC3F-F2AF35E4A6FAQ36237923-5B9F76ED-5070-442B-9839-2153DCA60CC8Q36459487-6AA87DDB-158C-4E65-95DD-C497EB4FBCBAQ36641540-397D1330-89EC-447C-A259-EE5E5FD0DE1FQ36862161-DB907FF7-7EEF-428F-8D24-4A47B737315FQ36994582-91E07A19-7A86-4A32-9987-08ED1C08E4C1Q37207391-48A372E4-EED0-4993-82CD-B9D45C519E43Q37535345-3DC73662-869F-437E-89B1-CDE6EC11C09AQ37544140-F6EE837E-E752-436E-8B44-622C8784A11BQ37843058-520C94EA-A167-4874-B206-98A2F9946909Q38587703-669FC25F-D72E-4E41-9BF1-0FE02411CF4DQ38748904-F2B2921F-6564-4A4C-ABB9-8B958AD493FDQ39011456-17279730-C193-45F8-8238-A27682E24084Q39192234-84C9CC55-31E7-41A7-949B-D6B9C53836FBQ39808275-F7824C9F-B4A0-4718-8C0E-F826DEBB1E08Q40281429-4764AA9D-6322-4AFD-BA5F-FFC6B958A22EQ41249640-CF1F83DD-77DC-41DC-A6E9-4094290129E3Q43947378-23B96CE8-5B1D-4D6B-B34D-A864211BDC5DQ44634755-1F93025E-341D-4C25-9D5D-A7BB4AD1CF5DQ44856297-D17CBAD5-0321-49B0-97FB-0D5BE57B1007Q51354007-1BDECF59-6631-4BF1-9354-C4EDB4ADCE11Q51669080-65031EA6-DC6E-4B95-AB1A-E522016E855AQ53506236-D2A412A7-0129-4472-BF4C-A583E76EC011
P2860
Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal
description
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
article
@en
im Mai 2001 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel (gepubliceerd op 2001/05/01)
@nl
наукова стаття, опублікована в травні 2001
@uk
مقالة علمية (نشرت في مايو 2001)
@ar
ലേഖനം
@ml
name
Anti-GQ1b ganglioside antibodi ...... on of the motor nerve terminal
@ast
Anti-GQ1b ganglioside antibodi ...... on of the motor nerve terminal
@en
type
label
Anti-GQ1b ganglioside antibodi ...... on of the motor nerve terminal
@ast
Anti-GQ1b ganglioside antibodi ...... on of the motor nerve terminal
@en
prefLabel
Anti-GQ1b ganglioside antibodi ...... on of the motor nerve terminal
@ast
Anti-GQ1b ganglioside antibodi ...... on of the motor nerve terminal
@en
P356
P1433
P1476
Anti-GQ1b ganglioside antibodi ...... on of the motor nerve terminal
@en
P2093
G. M. O'Hanlon
P304
P356
10.1093/BRAIN/124.5.893
P407
P577
2001-05-01T00:00:00Z